The Aliquot
Vega ShahThe Aliquot is a publication about biology and software, with a focus on the growing field of TechBio. I write about the intricacies of scientific research, breakthroughs in drug discovery, emerging trends in biotechnology, and dreams of the future.
| Platform |  | Pricing | Only free issues | Publishes | Infrequently |
|---|---|---|---|---|---|
| Issues | 10 | Founded | 3 years ago | Last Issue | a year ago |
| Active | |||||
Read this Newsletter
thealiquot.substack.comLatest Issues
Let There Be Drugs 2.0
The FDA's Center for Drug Evaluation and Research, CDER, approved 50 new therapeutics in 2024, slightly down from 55 in 2023 but still maintaining a robust 10-year rolling average of 46.5 novel approvals per year. This cohort brought severa...
Introducing TechBio Transformers
About a month ago, I hit my breaking point with how unwelcoming and disconnected the techbio and software communities had become. I vented about it online, and the response that followed was incredible. I got flooded with hundreds of commen...
Let There Be Drugs
2023 turned out to be a bumper year for FDA approvals with 71 new therapeutics! This was approximately double the number of approvals in 2022. It was an interesting year, not only due to the quantity of approvals but also because of the div...
Unlearning Bad Habits from Academia
When I made the transition from a postdoc to scientist at a biotech startup, I quickly realized that my work habits and even ideologies were not well suited for being productive in a company. In academia, PhD students operate under conditio...
Life Sciences Tech Investments in 2024
The Gartner report is a research document produced annually by Gartner Inc, a popular tech advisory firm. They survey executives around the world to predict industry trends and also how companies plan to spend their money each fiscal year....
Key Facts
Audience Metrics
Subscribers, engagement, traffic and sponsorship for The Aliquot.
| Subscribers | Monthly Web Visits | Accepts Sponsors | |||
|---|---|---|---|---|---|
| Estimated Cost per Ad | |||||
Explore More
Authors
The writers behind this newsletter.
Social
Frequently Asked Questions
How can I access the email archive for The Aliquot?
You can find recent issues that have been published by The Aliquot on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does The Aliquot have?
To see how many people subscribe to The Aliquot, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in The Aliquot?
Newsletter advertising can be extremely effective when it's done right. Before you pitch The Aliquot as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like The Aliquot?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact The Aliquot using the contact information provided and ask for a copy of their media kit.
How can I find newsletters related to The Aliquot?
Scroll up to where it says Related Newsletters to see other publications like The Aliquot. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact The Aliquot?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.